Your browser is no longer supported. Please, upgrade your browser.
Settings
VVUS [NASD]
VIVUS Inc.
Index- P/E- EPS (ttm)-0.80 Insider Own0.30% Shs Outstand103.89M Perf Week-9.96%
Market Cap244.14M Forward P/E- EPS next Y-0.85 Insider Trans480.70% Shs Float102.96M Perf Month-15.77%
Income-82.60M PEG- EPS next Q-0.22 Inst Own69.90% Short Float36.52% Perf Quarter-15.47%
Sales114.20M P/S2.14 EPS this Y53.80% Inst Trans2.45% Short Ratio15.14 Perf Half Y-39.12%
Book/sh0.80 P/B2.94 EPS next Y24.80% ROA-20.90% Target Price4.00 Perf Year-61.09%
Cash/sh2.88 P/C0.81 EPS next 5Y6.70% ROE-73.60% 52W Range2.41 - 6.28 Perf YTD-18.40%
Dividend- P/FCF- EPS past 5Y-1.80% ROI-16.10% 52W High-62.58% Beta1.13
Dividend %- Quick Ratio5.60 Sales past 5Y29.50% Gross Margin70.80% 52W Low-2.49% ATR0.17
Employees94 Current Ratio6.20 Sales Q/Q-50.80% Oper. Margin-39.00% RSI (14)35.56 Volatility5.49% 6.12%
OptionableYes Debt/Eq2.76 EPS Q/Q-47.10% Profit Margin-72.30% Rel Volume1.52 Prev Close2.46
ShortableYes LT Debt/Eq2.63 EarningsFeb 24 AMC Payout- Avg Volume2.48M Price2.35
Recom3.30 SMA20-15.71% SMA50-13.52% SMA200-34.80% Volume3,785,814 Change-4.47%
Jan-23-15Initiated RBC Capital Mkts Outperform $6
Feb-25-14Reiterated WallachBeth Hold $11 → $8
Nov-15-13Initiated WallachBeth Hold $11
Oct-03-13Upgrade Cowen Hold → Outperform $19
Jul-19-13Downgrade Needham Buy → Hold
Jan-18-13Reiterated MLV & Co Buy $40 → $21
Sep-24-12Reiterated Needham Buy $38 → $32
Jul-19-12Reiterated MLV & Co Buy $34 → $40
Jul-18-12Reiterated Rodman & Renshaw Mkt Outperform $39 → $52
Jul-18-12Downgrade Brean Murray Buy → Hold
Apr-30-12Reiterated MLV & Co Buy $30 → $34
Feb-23-12Upgrade Rodman & Renshaw Mkt Perform → Mkt Outperform $39
Feb-23-12Upgrade Brean Murray Sell → Hold $2
Feb-23-12Reiterated MLV & Co Buy $22 → $30
Feb-23-12Reiterated JMP Securities Mkt Outperform $16 → $45
Jan-17-12Reiterated MLV & Co Buy $16 → $22
Jan-05-12Initiated Rodman & Renshaw Mkt Perform
Oct-29-10Reiterated JMP Securities Mkt Outperform $12 → $16
Aug-03-10Downgrade Brean Murray Hold → Sell $2
Jul-16-10Reiterated Wedbush Outperform $20 → $10
Mar-30-15 04:31PM  VIVUS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
04:19PM  VIVUS Announces Operational Update at noodls
04:05PM  VIVUS Announces Operational Update Marketwired
Mar-27-15 10:06PM  A Look at Pharma Company Dermira's Performance
08:25AM  Ahead of the Bell: Orexigen shares rise
06:50AM  The young & the restless: 6 who are hot at CNBC
Mar-20-15 05:29PM  Ferrellgas, Prothena Lead Friday's After-Hours Movers
Mar-10-15 01:51PM  4 Stocks Under $10 Making Big Moves Higher at TheStreet
07:06AM  VIVUS INC Files SEC form 8-K, Other Events
Mar-09-15 07:58AM  Early movers: GM, RTI, AMZN, AAPL, BBRY & more at CNBC
07:06AM  VIVUS INC Files SEC form 8-K, Other Events
Mar-06-15 04:07PM  VIVUS INC Files SEC form 8-K, Change in Directors or Principal Officers
Mar-04-15 01:04PM  VIVUS INC Financials +6.81%
Mar-03-15 03:36PM  Nasdaq backs off from 5,000
01:54PM  Orexigen Soars On Obesity Drug's Surprise Health Boon at Investor's Business Daily
11:51AM  Orexigen Weight-Loss Pill Shows Surprise Heart-Safety Benefit at TheStreet
Feb-27-15 07:08PM  10-K for VIVUS, Inc. at Company Spotlight
Feb-26-15 11:07AM  Biotech Stock Roundup: Pharmacyclics Up on Buyout Rumors, Celgene Drug Label Expanded - Analyst Blog +5.91%
Feb-25-15 04:13PM  VIVUS INC Files SEC form 10-K, Annual Report EDGAR Online -8.96%
12:41PM  JPM Securities Picks Through Biotech News For Winners
09:40AM  VIVUS Q4 Loss Wider than Expected, Qsymia Disappoints - Analyst Blog
Feb-24-15 05:12PM  Vivus reports 4Q loss AP
04:30PM  VIVUS Inc Earnings Call scheduled for 4:30 pm ET today CCBN
04:07PM  VIVUS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits EDGAR Online
07:07AM  Q4 2014 Vivus Inc Earnings Release - After Market Close CCBN
Feb-20-15 03:47PM  Obesity Drugs: Orexigen Gains Market Share at Expense of Arena, Vivus at TheStreet +7.46%
11:24AM  Activists want 'imminent retirement' of Ariad CEO at CNBC
07:00AM  VIVUS to Present at Upcoming Investor Conference Marketwired
Feb-19-15 07:00AM  VIVUS Announces Date of Fourth Quarter and Year End 2014 Update and Financial Results Conference Call GlobeNewswire
Jan-29-15 07:09AM  VIVUS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online
07:00AM  VIVUS Announces European Approval of SPEDRA Label Amendment; SPEDRA Now First and Only Oral Erectile Dysfunction Treatment Approved in Europe to Be Taken Approximately 15 Minutes Before Sexual Activity Marketwired
Jan-27-15 04:06PM  VIVUS INC Files SEC form 8-K, Change in Directors or Principal Officers EDGAR Online
Jan-26-15 04:06PM  VIVUS INC Files SEC form 8-K, Change in Directors or Principal Officers EDGAR Online
Jan-23-15 06:25AM  Coverage initiated on Vivus by RBC Capital Mkts Briefing.com +6.20%
Jan-22-15 04:04PM  The 52-Week Low Club for Thursday at 24/7 Wall St. -5.15%
04:00PM  Arena Pharmaceuticals to Raise Fund Via Share Issuance - Analyst Blog Zacks
Jan-15-15 07:01AM  VIVUS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits EDGAR Online -7.33%
Jan-14-15 05:25PM  Obesity Device That Makes You Feel Full to Cost $15,000 at Bloomberg
01:55PM  5 Obesity Stocks Investors Are Watching Benzinga
Jan-13-15 04:05PM  VIVUS INC Files SEC form 8-K, Change in Directors or Principal Officers EDGAR Online -6.36%
Jan-09-15 07:00AM  VIVUS to Present at Upcoming Investor Conference Marketwired
Dec-23-14 04:49PM  FDA clears Novo Nordisk's weight loss drug Saxenda AP
Dec-19-14 02:09PM  Orexigen Therapeutics Gains On Diet Pill Nod From European Committee Benzinga
08:25AM  Orexigen's 'Goldilocks' Weight-Loss Pill is Just Right for European Regulators at TheStreet
Dec-17-14 07:42AM  Bio-Twitter Sentiment Favors European Orexigen Obesity Pill Approval Yahoo Finance Contributors
Dec-15-14 07:00AM  VIVUS Announces Favorable Formulary Positioning for Qsymia Marketwired
Dec-12-14 11:58AM  Obesity Pill Upstart Orexigen Therapeutics Gaining on Rivals Yahoo Finance Contributors
Dec-09-14 05:34AM  Others Overlooked VIVUS (VVUS), Should You Buy It Now? Zacks
Dec-02-14 03:00AM  Europe shares open higher; oil price watched CNBC
Dec-01-14 06:25PM  Cramer: State of holiday retail CNBC -5.67%
Nov-26-14 07:06AM  VIVUS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online
07:00AM  VIVUS Announces Issuance of Two Additional U.S. Patents for Qsymia Marketwired
Nov-19-14 05:48AM  Why VIVUS (VVUS) Might Be a Diamond in the Rough Zacks
Nov-13-14 12:10PM  What's Driving Orexigen Therapeutics Higher? Benzinga
Nov-12-14 04:07PM  VIVUS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits EDGAR Online
Nov-10-14 11:02AM  Orexigen rises as weight loss drug review proceeds AP
Nov-07-14 07:08PM  10-Q for VIVUS, Inc. Company Spotlight
Nov-06-14 03:45PM  VIVUS Posts Narrower-than-Expected Q3 Loss, Revenues Up Zacks
Nov-05-14 05:45PM  Vivus tops Street 3Q forecasts AP
04:30PM  Vivus Inc Earnings Call scheduled for 4:30 pm ET today CCBN
04:06PM  VIVUS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits EDGAR Online
04:00PM  VIVUS Reports Third Quarter 2014 Financial Results Marketwired
07:07AM  Q3 2014 Vivus Inc Earnings Release - After Market Close CCBN
Nov-03-14 07:00AM  VIVUS Announces Qsymia Presentations at Obesity Week 2014 Marketwired
Oct-30-14 07:00AM  VIVUS Announces Date of Third Quarter 2014 Update and Financial Results Conference Call GlobeNewswire
Oct-20-14 01:10PM  Notable option trades in equities optionMONSTER
Oct-09-14 07:00PM  Endo Buyout Of Auxilium Joins Two Changing Firms at Investor's Business Daily
Oct-08-14 04:50PM  Emergent BioSolutions Revamps Business to Drive Earnings Zacks
Oct-07-14 04:40PM  Halozyme's PEGPH20 Receives FDA Orphan Drug Designation Zacks -5.67%
Oct-06-14 07:00AM  Newly Published Data Highlight the Effects of Weight Loss With Qsymia in Type 2 Diabetes Marketwired
Oct-02-14 12:10PM  Zafgen Aims Obesity Drug At Rare, Deadly Disease at Forbes
Sep-30-14 10:37AM  [video] Zafgen CEO: 2015 Will Be Data Rich Year for Obesity Treatment at TheStreet
Sep-19-14 05:25PM  VIVUS and Auxilium Announce Stendra Label Expansion Zacks
08:14AM  VIVUS Inc. (VVUS) Rises: Stock Adds 12.4% in Session Zacks
Sep-18-14 05:25PM  Rite Aid and Pier 1 are big market movers AP +12.37%
03:45PM  UPDATE 1-Vivus' Stendra gets FDA approval for use 15 minutes before sex Reuters
12:34PM  Pier 1 punished, Vivus lifting off, Amazon unveils new Kindles Yahoo Finance
12:21PM  FDA OKs faster-acting label for ED drug Stendra AP
12:09PM  VIVUS, Inc.s Stendra lets you get it up faster Yahoo Finance Blogs
11:00AM  [$$] Stendra Gets FDA Approval as 'On-Demand' Drug at The Wall Street Journal
10:17AM  Why VIVUS (VVUS) Stock Is Up Today at TheStreet
09:55AM  Vivus, Inc. Opens Sharply Higher On ED Drug Marketing Approval Benzinga
08:31AM  Pharmalot, Pharmalittle: We're Reading About Vivus, Gilead and Lots More!! at The Wall Street Journal
07:37AM  Faster-acting erectile dysfunction drug gets FDA approval Reuters
06:05AM  VIVUS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online
06:00AM  VIVUS And Auxilium Announce FDA Approval Of STENDRA sNDA; STENDRA Now First And Only Oral Erectile Dysfunction Treatment Approved To Be Taken Approximately 15 Minutes Before Sexual Activity PR Newswire
06:00AM  VIVUS and Auxilium Announce FDA Approval of STENDRA sNDA; STENDRA Now First and Only Oral Erectile Dysfunction Treatment Approved to Be Taken Approximately 15 Minutes Before Sexual Activity Marketwired
Sep-16-14 04:05PM  VIVUS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders EDGAR Online
09:48AM  Doc Offers Glimpse Into Arena Pharma Weight-Loss Combination Therapy at TheStreet
Sep-11-14 05:15PM  [video] Orexigen drops in spite of FDA approval at CNBC
04:10PM  How Will Orexigen Therapeutics (OREX) Stock Respond to FDA's Contrave Approval? at TheStreet
04:00PM  U.S. FDA panel: Novo Nordisk's liraglutide safe/effective for obesity Reuters
01:23PM  Orexigen's Obesity Pill is Approved and Stock Falls. Don't be Surprised at TheStreet
12:50PM  [$$] FDA Approves Weight-Loss Drug at The Wall Street Journal
07:18AM  FDA approves weight-loss drug Contrave AP
Sep-10-14 09:16PM  New Drug to Treat Obesity Gains Approval by F.D.A. at New York Times
07:58PM  FDA Approves Contrave Weight Loss Drug From Orexigen And Takeda at Forbes
07:00PM  Orexigen Wins U.S. FDA Approval for Weight-Loss Pill at Bloomberg
Sep-09-14 09:32AM  FDA staff: Novo Nordisk drug liraglutide effective for obesity Reuters
Aug-28-14 04:06PM  VIVUS INC Files SEC form 8-K, Entry into a Material Definitive Agreement EDGAR Online
VIVUS, Inc., a biopharmaceutical company, develops and commercializes therapies to address unmet needs in obesity, sleep apnea, diabetes, and sexual health in the United States and the European Union. The company offers Qsymia for the treatment of obesity as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index of 30 or greater, or 27 or greater in the presence of at least one weight-related comorbidity, such as hypertension, type 2 diabetes mellitus, or high cholesterol; and STENDRA, an oral phosphodiesterase type 5 inhibitor for the treatment of erectile dysfunction. It is also developing Qsymia, which has completed Phase II studies for the treatment of obstructive sleep apnea and diabetes, as well as for other obesity-related diseases, including nonalcoholic steatohepatitis, nonalcoholic fatty liver disease, hyperlipidemia, and hypertension. The company has development, license and clinical trial, and commercial supply agreement with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of avanafil, a PDE5 inhibitor compound for the oral and local treatment of male and female sexual dysfunction. It also has license and commercialization agreements with Berlin-Chemie AG and Auxilium Pharmaceuticals, Inc. to commercialize and promote SPEDRA; and with Sanofi Winthrop Industrie to commercialize and promote avanafil. VIVUS, Inc. was founded in 1991 and is headquartered in Mountain View, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Day WesleyVP, Clinical DevelopmentJan 29Sale2.784721,31256,999Jan 30 04:15 PM
Sanford Svai SCFO & Chief Accounting OfficerJan 29Sale2.784721,31265,559Jan 30 04:14 PM
MARSH GUY PVP, US Operations & GMJan 29Sale2.7823866231,487Jan 30 04:14 PM
Slebir John LSVP, Business Development & GCJan 29Sale2.786301,75172,799Jan 30 04:14 PM
NORTH TIDE CAPITAL, LLC10% OwnerJan 08Buy3.22217,900701,64012,500,000Jan 09 04:37 PM
NORTH TIDE CAPITAL, LLC10% OwnerJan 07Buy3.05282,100859,70112,282,100Jan 09 04:37 PM
NORTH TIDE CAPITAL, LLC10% OwnerJan 06Buy3.03147,936448,79812,000,000Jan 07 04:14 PM
NORTH TIDE CAPITAL, LLC10% OwnerJan 05Buy3.05328,8641,002,37111,852,064Jan 07 04:14 PM
NORTH TIDE CAPITAL, LLC10% OwnerJan 02Buy2.99218,400652,84511,523,200Jan 05 04:21 PM
NORTH TIDE CAPITAL, LLC10% OwnerDec 31Buy2.83304,800862,68011,304,800Jan 05 04:21 PM